<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291082</url>
  </required_header>
  <id_info>
    <org_study_id>S53057</org_study_id>
    <nct_id>NCT01291082</nct_id>
  </id_info>
  <brief_title>Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)</brief_title>
  <acronym>METAMARBO</acronym>
  <official_title>Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiÃ«nten Met Een Borstcarcinoom (MetaMaRBo)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging
      (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 50 patients with a proven breast cancer and bone metastases will be included.

      First step : staging

        -  nuclear bone scan

        -  Positron Emission Tomography (PET/CT)

        -  MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and
           Diffusion weighted imaging (DWI),no contrast administration

      Aim :

        -  Validation of whole body diffusion weighted imaging in detection of bone metastases and
           visceral metastases, comparing to Bone scan en PET/CT results.

        -  To calculate cut-off values for DWI for bone and visceral metastases.

      Second step : therapy follow-up/therapy assessment.

        -  Two groups of patients (oncologist takes the decision about therapy)

             1. Patients treated by chemotherapy

             2. Patients treated by hormonal therapy

        -  on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR
           (same protocol, no contrast) will be performed.

      End-point:

      Whole body MR with DWI is useful and reliable to assess the treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of whole body diffusion weighted MRI in breastcancer patients</measure>
    <time_frame>6 months</time_frame>
    <description>whole body MRI will be correlated to the nucleair bone scan and PET-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer patients</arm_group_label>
    <description>Breast cancer patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a proven breast cancer (by biopsy or imaging)

          2. Bone metastases proven by MR, PET-CT or Bone. Patients with visceral metastases can be
             included if bone metastases are also present.

          3. Patient with an informed consent.

        Exclusion Criteria:

          1. Patients with a single bone metastasis treated by Radiotherapy will be excluded.

          2. Patients with contra-indication for MRI: pacemaker, cochlear implant, non MR
             compatible devices (Baclofenpump).

          3. Claustrophobia

          4. Patient in a bad general condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Pans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven Dept Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Pans</last_name>
    <phone>003216340505</phone>
    <email>steven.pans@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Pans, MD</last_name>
      <phone>003216340505</phone>
      <email>steven.pans@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Steven Pans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>January 26, 2013</last_update_submitted>
  <last_update_submitted_qc>January 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Steven Pans</investigator_full_name>
    <investigator_title>Medical Doctor radiologist</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>metastasis</keyword>
  <keyword>bone</keyword>
  <keyword>diffusion MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

